Shopping Cart 0
Cart Subtotal
USD 0

Oncodesign SA (ALONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Oncodesign SA (Oncodesign) is a biopharmaceutical company, specializing in precision medicine offers drug discovery and pharmacological evaluation services for cancer. Its service offerings include integrated drug discovery; metabolic and pharmacokinetic characteristics of chemical and biological substances; assessment and validation of anti-cancer therapies, biomarker development and monitoring, translational biomarkers, and biodecontamination services. Oncodesign's technological platforms includes PREDICT, a conventional in vitro and in vivo pharmacology platform; Chi-Mice that concentrates on developing in vivo chimeric experimental models; Pharm'Image, a multi-modal and non-invasive pharmaco-imaging platform; and Nanocyclix, for the synthesis and optimization of novel compounds used for diagnostic and therapeutic purpose, among others. The company has its operations in Europe and the Americas. Oncodesign is headquartered in Dijon, France.

Oncodesign SA (ALONC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncodesign SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oncodesign SA, Medical Devices Deals, 2012 to YTD 2018 10

Oncodesign SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Oncodesign SA, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Oncodesign Acquires Service Businesses from Bertin Pharma 12

Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 13

Partnerships 14

Ipsen Partners with Oncodesign 14

Oncodesign Enters into Agreement with Bristol-Myers Squibb 15

Oncodesign Enters Into Research Agreement With Sanofi 16

Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 17

Sanofi Enters Into Research Agreement With Oncodesign 19

Oncodesign Enters into Research Agreement with Ipsen 20

Licensing Agreements 21

UCB Exercises Option for Licensing Agreement with Oncodesign 21

Equity Offering 22

Oncodesign Raises Funds through Private Placement of Shares 22

Oncodesign Raises USD17.8 Million in IPO 23

Oncodesign SA-Key Competitors 24

Oncodesign SA-Key Employees 25

Oncodesign SA-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Financial Announcements 27

Sep 26, 2018: Oncodesign: 1st Half 2018 Results 27

Jul 24, 2018: ONCODESIGN: Very strong revenue growth of 58% to EUR9.2 million in the first half of 2018 29

Apr 11, 2018: Oncodesign: 2017 annual results 30

Jan 30, 2018: Oncodesign Reports Total Sales Of EUR14.41m In 2017 32

Sep 19, 2017: Oncodesign: First-Half 2017 Results 33

Jul 20, 2017: Oncodesign: Stable Revenue in the First Half of 2017 35

Mar 30, 2017: ONCODESIGN: Business update and FY 2016 results 36

Jan 31, 2017: Oncodesign reports its FY 2016 revenue 38

Corporate Communications 40

Apr 23, 2018: Oncodesign Announces the Nomination of Arnaud Lafforgue as Chief Financial Officer 40

Government and Public Interest 41

Feb 07, 2017: Oncodesign's OncoSNIPE collaborative programme receives EUR7.7 million in support from the Investments for the Future Programme operated by Bpifrance 41

Product News 42

Dec 05, 2017: Oncodesign reports positive results for its MNK1/2 program 42

Other Significant Developments 43

Oct 18, 2017: OncoSNIPE Artificial Intelligence Project Officially Launched 43

Oct 18, 2017: Oncodesign: OncoSNIPE artificial intelligence project officially launched 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Oncodesign SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncodesign SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oncodesign SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Oncodesign SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncodesign SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncodesign SA, Deals By Therapy Area, 2012 to YTD 2018 9

Oncodesign SA, Medical Devices Deals, 2012 to YTD 2018 10

Oncodesign SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Oncodesign Acquires Service Businesses from Bertin Pharma 12

Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 13

Ipsen Partners with Oncodesign 14

Oncodesign Enters into Agreement with Bristol-Myers Squibb 15

Oncodesign Enters Into Research Agreement With Sanofi 16

Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 17

Sanofi Enters Into Research Agreement With Oncodesign 19

Oncodesign Enters into Research Agreement with Ipsen 20

UCB Exercises Option for Licensing Agreement with Oncodesign 21

Oncodesign Raises Funds through Private Placement of Shares 22

Oncodesign Raises USD17.8 Million in IPO 23

Oncodesign SA, Key Competitors 24

Oncodesign SA, Key Employees 25

Oncodesign SA, Other Locations 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Oncodesign SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.